Israeli cell therapy could treat respiratory effects caused by coronavirus

2020-03-19T07:39:43+00:00March 19th, 2020|General Health, Medical|0 Comments

Pluristem, a regenerative medicine company based in Haifa, Israel claims to have produced a cell therapy product that can be used to treat respiratory and inflammatory problems. These problems are often associated with the COVID-19 symptoms. Mr. Yaky Yanav, President and CEO of Pluristem, states that the healthcare system can be utilized to maintain and contain COVID-19.  BCRT and BIH, Berlin and Pluristem, are joining hands to inspect the therapeutic effects of Pluristem’s patented PLX cell product. They are proposing to test the system on patients with a pre-existing respiratory condition and aging patients.

The PLX cells induce the immune system’s natural regulatory T cells and M2 macrophages, which could reduce the symptoms of pneumonia and pneumonitis.

The company’s product is available off-the-shelf. The company is also well equipped for large-scale production. This is an added advantage as more people with respiratory conditions can be treated soon enough.

Source: https://www.jpost.com/HEALTH-SCIENCE/Israeli-cell-therapy-to-treat-acute-COVID-19-patients-prevent-ARDS-621016

Interested may kindly contact –

Ms. Veshala Gajaraj

Trade and Economic Dept.

Consulate General of the State of Israel to South India

Email: veshalalakshe.gajaraj@israeltrade.gov.il   Tel: +91-80-49406517

Leave A Comment